Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 4, 2010, Pages 367-378

  Kato, Motohiro ^a   Chiba, Koji ^b   Ito, Takashi ^c   Koue, Toshiko ^d   Sugiyama, Yuichi ^e  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP3A4; Drug discovery; Interindividual variability; Monte carlo simulation; Physiologically based pharmacokinetics; Prediction

Indexed keywords

ALFENTANIL; ALPRAZOLAM; ATORVASTATIN; BUSPIRONE; CISAPRIDE; CLARITHROMYCIN; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 3A4; DAPSONE; DELAVIRDINE; DIAZEPAM; EFAVIRENZ; ERYTHROMYCIN; ETOPOSIDE; FELODIPINE; FINASTERIDE; INDINAVIR; LORATADINE; METHYLPREDNISOLONE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PIMOZIDE; PREDNISOLONE; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; DISPERSION; DRUG CLEARANCE; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; ENZYME SUBSTRATE COMPLEX; EUROPEAN AMERICAN; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPANESE; LIVER BLOOD FLOW; LIVER MICROSOME; LIVER WEIGHT; MATHEMATICAL MODEL; MONTE CARLO METHOD; PREDICTION;

EID: 77956973148     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-09-RG-038     Document Type: Article

References (85)

1. Jonsson, E. N. and Sheiner, L. B.: More efficient clinical trials through use of scientific model-based statistical tests. Clin. Pharmacol. Ther., 72: 603-614 (2002).
2. Wade, J. R. and Sambol, N. C.: Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin. Pharmacol. Ther., 57: 569-581 (1995).
3. Kang, D., Verotta, D., Krecic-Shepard, M. E., Modi, N. B., Gupta, S. K. and Schwartz, J. B.: Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin. Pharmacol. Ther., 73: 31-40 (2003).
4. Vesell, E. S. and Page, J. G.: Genetic control of dicumarol levels in man. J. Clin. Invest., 47: 2657-2663 (1968).
5. Rasmussen, B. B., Brix, T. H., Kyvik, K. O. and Brosen, K.: The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics, 12: 473-478 (2002).
6. Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S. and Echizen, H.: Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-ex-pressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics, 8: 365-373 (1998).
7. Ingelman-Sundberg, M., Oscarson, M. and McLellan, R. A.: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20: 342-349 (1999).
8. Kirchheiner, J. and Brockmoller, J.: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 77: 1-16 (2005).
9. Izzo, A. A.: Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int. J. Clin. Pharmacol. Ther., 42: 139-148 (2004).
10. Zevin, S. and Benowitz, N. L.: Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet., 36: 425-438 (1999).
11. Sica, D. A.: Interaction of grapefruit juice and calcium channel blockers. Am. J. Hypertens., 19: 768-773 (2006).
12. Rostami-Hodjegan, A. and Tucker, G. T.: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov., 6: 140-148 (2007).
13. Howgate, E. M., Rowland, Yeo K., Proctor, N. J., Tucker, G. T. and Rostami-Hodjegan, A.: Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica, 36: 473-497 (2006).
14. Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Wood-house, K. W. and James, O. F.: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatolo-gy, 9: 297-301 (1989).
15. Zoli, M., Magalotti, D., Bianchi, G., Gueli, C., Orlandini, C., Grimaldi, M. and Marchesini, G.: Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing, 28: 29-33 (1999).
16. Panton, L. B., Guillen, G. J., Williams, L., Graves, J. E., Vivas, C., Cediel, M., Pollock, M. L., Garzarella, L., Krumerman, J., Derendorf, H. and et al.: The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. J. Clin. Pharmacol., 35: 885-894 (1995).
17. Pirttiaho, H. I., Sotaniemi, E. A., Pelkonen, R. O. and Pitkanen, U.: Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur. J. Clin. Pharmacol., 22: 441-445 (1982).
18. Tanaka, G. I., Kawamura, H. and Nakahara, Y.: Reference Japanese man-I. Mass of organs and other characteristics of normal Japanese. Health Phys., 36: 333-346 (1979).
19. Kerremans, A. L., Gribnau, F. W., Tan, Y. and van Ginneken, C. A.: Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers. Eur. J. Clin. Pharmacol., 22: 515-521 (1982).
20. Gorski, J. C., Hall, S. D., Becker, P., Affrime, M. B., Cutler, D. L. and Haehner-Daniels, B.: In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin. Pharmacol. Ther., 67: 32-43 (2000).
21. Matsushita, Y., Eiki, J., Tsukiori, M., Suzuki, T. and Moriguchi, I.: Binding of drugs to sera of patients with renal disease and liver disease. Chem. Pharm. Bull. (Tokyo), 35: 308-314 (1987).
22. Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G. and Thummel, K. E.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol., 62: 162-172 (2002).
23. Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Hartwell, P. S., Raisys, V. A., Marsh, C. L., McVi-car, J. P., Barr, D. M. et al.: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther., 271: 549-556 (1994).
24. Sy, S. K., Ciaccia, A., Li, W., Roberts, E. A., Okey, A., Kalow, W. and Tang, B. K.: Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur. J. Clin. Pharmacol., 58: 357-365 (2002).
25. Tateishi, T., Watanabe, M., Moriya, H., Yamaguchi, S., Sato, T. and Kobayashi, S.: No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol., 57: 935-939 (1999).
26. Shimada, T., Tsumura, F. and Yamazaki, H.: Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab. Dispos., 27: 1274-1280 (1999).
27. Walsh, S. L., Johnson, R. E., Cone, E. J. and Bigelow, G. E.: Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. J. Pharmacol. Exp. Ther., 285: 71-82 (1998).
28. Bodenham, A. and Park, G. R.: Alfentanil infusions in patients requiring intensive care. Clin. Pharmacokinet., 15: 216-226 (1988).
29. Greenblatt, D. J. and Wright, C. E.: Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin. Pharmacokinet., 24: 453-471 (1993).
30. Gibson, D. M., Bron, N. J., Richens, A., Hounslow, N. J., Sed-man, A. J. and Whitfield, L. R.: Effect of age and gender on phar-macokinetics of atorvastatin in humans. J. Clin. Pharmacol., 36: 242-246 (1996).
31. Gammans, R. E., Mayol, R. F. and LaBudde, J. A.: Metabolism and disposition of buspirone. Am. J. Med., 80: 41-51 (1986).
32. Barbhaiya, R. H., Shukla, U. A., Pfeffer, M., Pittman, K. A., Shrotriya, R., Laroudie, C. and Gammans, R. E.: Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur. J. Clin. Pharmacol., 46: 41-47 (1994).
33. Barone, J. A., Huang, Y. C., Bierman, R. H., Colaizzi, J. L., Long, J. F., Kerr, D. A., Van Peer, A., Woestenborghs, R. and Heykants, J.: Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. Clin. Pharm., 6: 640-645 (1987).
34. Fraschini, F., Scaglione, F. and Demartini, G.: Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet., 25: 189-204 (1993).
35. Berlin, A. and Dahlstrom, H.: Pharmacokinetics of the anticon-vulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. Eur. J. Clin. Pharmacol., 9: 155-159 (1975).
36. Grochow, L. B. and Colvin, M.: Clinical pharmacokinetics of cy-clophosphamide. Clin. Pharmacokinet., 4: 380-394 (1979).
37. Fahr, A.: Cyclosporin clinical pharmacokinetics. Clin. Phar-macokinet., 24: 472-495 (1993).
38. Pieters, F. A. and Zuidema, J.: The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br. J. Clin. Pharmacol., 22: 491-494 (1986).
39. Venkatesan, K.: Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharmacokinet., 16: 365-386 (1989).
40. Morse, G. D., Fischl, M. A., Shelton, M. J., Cox, S. R., Driver, M., DeRemer, M. and Freimuth, W. W.: Single-dose phar-macokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother., 41: 169-174 (1997).
41. Friedman, H., Greenblatt, D. J., Peters, G. R., Metzler, C. M., Charlton, M. D., Harmatz, J. S., Antal, E. J., Sanborn, E. C. and Francom, S. F.: Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin. Pharmacol. Ther., 52: 139-150 (1992).
42. Adkins, J. C. and Noble, S.: Efavirenz. Drugs, 56: 1055-1064; discussion 1065-1056 (1998).
43. Villani, P., Regazzi, M. B., Castelli, F., Viale, P., Torti, C., Semi-nari, E. and Maserati, R.: Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br. J. Clin. Pharmacol., 48: 712-715 (1999).
44. Periti, P., Mazzei, T., Mini, E. and Novelli, A.: Clinical phar-macokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin. Phar-macokinet., 16: 193-214 (1989).
45. Clark, P. I. and Slevin, M. L.: The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet., 12: 223-252 (1987).
46. Dunselman, P. H. and Edgar, B.: Felodipine clinical pharmacoki-netics. Clin. Pharmacokinet., 21: 418-430 (1991).
47. Sudduth, S. L. and Koronkowski, M. J.: Finasteride: the first 5 al-pha-reductase inhibitor. Pharmacotherapy, 13: 309-325; discussion 325-329 (1993).
48. Yeh, K. C., Deutsch, P. J., Haddix, H., Hesney, M., Hoagland, V., Ju, W. D., Justice, S. J., Osborne, B., Sterrett, A. T., Stone, J. A., Woolf, E. and Waldman, S.: Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother., 42: 332-338 (1998).
49. Haria, M., Fitton, A. and Peters, D. H.: Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs, 48: 617-637 (1994).
50. Rohatagi, S., Barth, J., Mollmann, H., Hochhaus, G., Soldner, A., Mollmann, C. and Derendorf, H.: Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J. Clin. Pharmacol., 37: 916-925 (1997).
51. Tornatore, K. M., Reed, K. A. and Venuto, R. C.: Methylpred-nisolone and cortisol metabolism during the early post-renal transplant period. Clin. Transplant., 9: 427-432 (1995).
52. Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D. and Wilkinson, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther., 59: 491-502 (1996).
53. Luzuriaga, K., Bryson, Y., McSherry, G., Robinson, J., Stechen-berg, B., Scott, G., Lamson, M., Cort, S. and Sullivan, J. L.: Phar-macokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J. Infect. Dis., 174: 713-721 (1996).
54. Barry, M., Mulcahy, F., Merry, C., Gibbons, S. and Back, D.: Pharmacokinetics and potential interactions amongst an-tiretroviral agents used to treat patients with HIV infection. Clin. Pharmacokinet., 36: 289-304 (1999).
55. Renwick, A. G., Robertson, D. R., Macklin, B., Challenor, V., Waller, D. G. and George, C. F.: The pharmacokinetics of oral nifedipine-a population study. Br. J. Clin. Pharmacol., 25: 701-708 (1988).
56. Soons, P. A., Schoemaker, H. C., Cohen, A. F. and Breimer, D. D.: Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects. J. Clin. Pharmacol., 32: 324-331 (1992).
57. van Harten, J., van Brummelen, P., Lodewijks, M. T., Danhof, M. and Breimer, D. D.: Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin. Pharmacol. Ther., 43: 332-341 (1988).
58. Soons, P. A., Vogels, B. A., Roosemalen, M. C., Schoemaker, H. C., Uchida, E., Edgar, B., Lundahl, J., Cohen, A. F. and Breimer, D. D.: Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin. Pharmacol. Ther., 50: 394-403 (1991).
59. Sallee, F. R., Pollock, B. G., Stiller, R. L., Stull, S., Everett, G. and Perel, J. M.: Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. J. Clin. Pharmacol., 27: 776-781 (1987).
60. Pickup, M. E.: Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet., 4: 111-128 (1979).
61. Sawyer, W. T., Pulliam, C. C., Mattocks, A., Foster, J., Hadzija, B. W. and Rosenthal, H. M.: Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution. Biopharm. Drug Dispos., 3: 301-310 (1982).
62. Ueda, C. T., Williamson, B. J. and Dzindzio, B. S.: Absolute quinidine bioavailability. Clin. Pharmacol. Ther., 20: 260-265 (1976).
63. Krishna, S. and White, N. J.: Pharmacokinetics of quinine, chlo-roquine and amodiaquine. Clinical implications. Clin. Phar-macokinet., 30: 263-299 (1996).
64. Hatorp, V., Oliver, S. and Su, C. A.: Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int. J. Clin. Pharmacol. Ther., 36: 636-641 (1998).
65. Hatorp, V., Walther, K. H., Christensen, M. S. and Haug-Pihale, G.: Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J. Clin. Pharmacol., 40: 142-152 (2000).
66. Hsu, A., Granneman, G. R. and Bertz, R. J.: Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet., 35: 275-291 (1998).
67. Walker, D. K., Ackland, M. J., James, G. C., Muirhead, G. J., Rance, D. J., Wastall, P. and Wright, P. A.: Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 29: 297-310 (1999).
68. Lilja, J. J., Neuvonen, M. and Neuvonen, P. J.: Effects of regular consumption of grapefruit juice on the pharmacokinetics of sim-vastatin. Br. J. Clin. Pharmacol., 58: 56-60 (2004).
69. Zimmerman, J. J., Ferron, G. M., Lim, H. K. and Parker, V.: The effect of a high-fat meal on the oral bioavailability of the im-munosuppressant sirolimus (rapamycin). J. Clin. Pharmacol., 39: 1155-1161 (1999).
70. Bekersky, I., Dressler, D. and Mekki, Q. A.: Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg. Clin. Ther., 21: 2058-2064 (1999).
71. Anttila, M., Laakso, S., Nylanden, P. and Sotaniemi, E. A.: Phar-macokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin. Pharmacol. Ther., 57: 628-635 (1995).
72. Nilsen, O. G. and Dale, O.: Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol. Toxicol., 71: 150-153 (1992).
73. Garzone, P. D. and Kroboth, P. D.: Pharmacokinetics of the newer benzodiazepines. Clin. Pharmacokinet., 16: 337-364 (1989).
74. Echizen, H. and Eichelbaum, M.: Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin. Pharmacokinet., 11: 425-449 (1986).
75. McTavish, D. and Sorkin, E. M.: Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs, 38: 19-76 (1989).
76. Patat, A., Trocherie, S., Thebault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Court, L. A. and Morselli, P. L.: EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacol-ogy (Berl), 114: 138-146 (1994).
77. Wilkinson, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev., 39: 1-47 (1987).
78. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizu-no, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., Kusuhara, H., Ito, K. and Sugiyama, Y.: The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quan-titative analysis based on information from the literature. Drug Metab. Pharmacokinet., 18: 365-372 (2003).
79. Tateishi, T., Watanabe, M., Nakura, H., Asoh, M., Shirai, H., Mizorogi, Y., Kobayashi, S., Thummel, K. E. and Wilkinson, G. R.: CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin. Pharmacol. Ther., 69: 333-339(2001).
80. Kharasch, E. D., Walker, A., Hoffer, C. and Sheffels, P.: Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin. Pharmacol. Ther., 76: 452-466 (2004).
81. Masica, A. L., Mayo, G. and Wilkinson, G. R.: In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther., 76: 341-349(2004).
82. Hellriegel, E. T., Bjornsson, T. D. and Hauck, W. W.: Inter-patient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther., 60: 601-607 (1996).
83. Rawden, H. C, Carlile, D. J., Tindall, A., Hallifax, D., Galetin, A., Ito, K. and Houston, J. B.: Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica, 35: 603-625 (2005).
84. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chi-ba, K., Ishizaki, T., Green, C. E., Tyson, C. A. and Sugiyama, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73: 147-171 (1997).
85. Gibbons, J., Egorin, M. J., Ramanathan, R. K., Fu, P., Mulkerin, D. L., Shibata, S., Takimoto, C. H., Mani, S., LoRusso, P. A., Grem, J. L., Pavlick, A., Lenz, H. J., Flick, S. M., Reynolds, S., Lagattuta, T. F., Parise, R. A., Wang, Y., Murgo, A. J., Ivy, S. P. and Remick, S. C: Phase I and pharmacokinetic study of im-atinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol., 26: 570-576 (2008).